A variety of putative prostate cancer markers have been described in human serum, urine, seminal fluid, and histological specimens. These markers exhibit varying capacities to detect prostate cancer and to predict disease course. In order to be considered markers for diagnosis or prognosis of disease course, and to be brought forward for large-scale clinical evaluation, they should fulfill several criteria. Firstly, there should be a biological or therapeutic rationale for choosing the marker, or at least a consistent association with disease presence, disease characteristics such as stage, or disease aggressiveness. Secondly, there should be an assessment of the strength of marker association with disease outcome. Thirdly, the marker should be assessed as an independent predictor in a multivariate analysis.
JemalA., SiegelR., WardE., MurrayT., XuJ., ThunM.J.. Cancer statistics, 2007.CA Cancer J Clin.2007; 57: 43–66.
2.
StameyT.A., DonaldsonA.N., YemotoC.E., McNealJ.E., SözenS., GillH.. Histological and clinical findings in 896 consecutive prostates treated only with radical retropubic prostatectomy: epidemiologic significance of annual changes.J Urol1998; 160: 2412–17.
3.
StameyT.A., JohnstoneI.M., McNealJ.E., LuA.Y., YemotoC.M.. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng/ml.J Urol2002; 167: 103–11.
4.
HoroszewiczJ.S., KawinskiE., MurphyG.P.. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients.Anticancer Res1987; 7: 927–35.
5.
PintoJ.T., SuffolettoB.P., BerzinT.M.Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells.Clin Cancer Res1996; 2: 1445–51.
6.
ThompsonT.C., TimmeT.L., LiL.Molecular pathways underlying prostate cancer progression. In: Prostate cancer: biology, genetics, and the new therapeutics edited by LelandW.K., ChungL.W.K., WilliamB., IsaacsW.B., JonathanW., SimonsJ.W., TotowaN.J., Humana Press Inc., 2001, 307.
7.
MurphyG.P., KennyG.M., RagdeH.Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer.Urology1998; 51: 89–97.
8.
BostwickD.G., PacelliA., BluteM., RocheP., MurphyG.P.. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases.Cancer1998; 82: 2256–61.
9.
TroyerJ.K., BeckettM.L., WrightGLJr.Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids.Int J Cancer1995; 62: 552–8.
10.
BeckettM.L., CazaresL.H., VlahouA., SchellhammerP.F., WrightGLJr.Prostate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer.Clin Cancer Res1999; 5: 4034–40.
11.
DouglasT.H., MorganT.O., McLeodD.G.Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients.Cancer1997; 80: 107–14.
12.
WrightG.L.Jr., GrobB.M., HaleyC.Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy.Urology1996; 48: 326–34.
13.
XiaoZ., AdamB.L., CazaresL.H.Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease.Cancer Res2001; 61: 6029–33.
14.
TjoaB., BoyntonA., KennyG., RagdeH., MisrockS.L., MurphyG.. Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity.Prostate1996; 28: 65–9.
15.
O'KeefeD.S., UchidaA., BacichD.J.Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer.Prostate2000; 45: 149–57.
16.
UríaJ.A., VelascoG., SantamaríaI., FerrandoA., López-OtínC.. Prostate-specific membrane antigen in breast carcinoma.Lancet1997; 349: 1601.
17.
HerrmannE., BögemannM., BiererS., EltzeE., HertleL., WülfingC.. the endothelin axis in urologic tumor: mechanisms of tumor biology and therapeutic implications.Expert Review of Anticancer Therapy2006; 6: 73–81.
18.
MontironiR., MazzucchelliR., BarbisanF.Immunohistochemical expression of endothelin-1 and endothelin-A and endothelin-B receptors in high-grade prostatic intraepithelial neoplasia and prostate cancer.Eur Urol2007; 52: 1682–89.
19.
HayesJ.D., PulfordD.J.. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance.Crit Rev Biochem Mol Biol1995; 30: 445–600.
20.
JerónimoC., UsadelH., HenriqueR.Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma.J Natl Cancer Inst2001; 93: 1747–52.
21.
BrooksJ.D., WeinsteinM., LinX.CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia.Cancer Epidemiol Biomarkers Prev1998; 7: 531–36.
22.
ChuD.C., ChuangC.K., FuJ.B., HuangH.S., TsengC.P., SunC.F.. The use of real-time quantitative polymerase chain reaction to detect hypermethylation of the CpG islands in the promoter region flanking the GSTP1 gene to diagnose prostate carcinoma.J Urol2002; 167: 1854–58.
23.
CooksonM.S., ReuterV.E., LinkovI., FairW.R.. Glutathione Stransferase PI (GST-pi) class expression by immunohistochemistry in benign and malignant prostate tissue.J Urol1997; 157: 673–76.
24.
GsurA., HaidingerG., HintereggerS.Polymorphisms of glutathione-S-transferase genes (GSTP1, GSTM1 and GSTT1) and prostate-cancer risk.Int J Cancer2001; 95: 152–55.
25.
Kote-JaraiZ., EastonD., EdwardsS.M.CRC/BPG UK Familial Prostate Cancer Study Collaborators. Relationship between glutathione S-transferase M1, P1 and T1 polymorphisms and early onset prostate cancer.Pharmacogenetics2001; 11: 325–30.
26.
MaruyamaR., ToyookaS., ToyookaK.O.Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features.Clin Cancer Res2002; 8: 514–19.
27.
LinX., AsgariK., PutziM.J.Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione Stransferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide.Cancer Res2001; 61: 8611–16.
28.
MontironiR., MazzucchelliR., BarbisanF.HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer.Hum Pathol2006; 37: 1137–44.
29.
RossJ.S., FletcherJ.A.. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.Stem Cells1998; 16: 413–28.
30.
YehS., LinH.K., KangH.Y., ThinT.H., LinM.F., ChangC.. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells.Proc Natl Acad Sci USA1999; 96: 5458–63.
31.
ReiterR.E., GuZ., WatabeT.Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer.Proc Natl Acad Sci U S A1998; 95: 1735–40.
32.
GuZ., ThomasG., YamashiroJ.Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer.Oncogene2000; 19: 1288–96.
33.
HaraN., KasaharaT., KawasakiT.Reverse transcription-polymerase chain reaction detection of prostate-specific antigen, prostate-specific membrane antigen, and prostate stem cell antigen in one milliliter of peripheral blood: value for the staging of prostate cancer.Clin Cancer Res2002; 8: 1794–99.
34.
ChristiansenJ.J., RajasekaranS.A., MoyP.Polarity of prostate specific membrane antigen, prostate stem cell antigen, and prostate specific antigen in prostate tissue and in a cultured epithelial cell line.Prostate2003; 55: 9–19.
35.
RossS., SpencerS.D., HolcombI.Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate.Cancer Res2002; 62: 2546–53.
36.
DannullJ., DienerP.A., PriklerL.Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer.Cancer Res2000; 60: 5522–28.
37.
ReiterR.E., SatoI., ThomasG.Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer.Genes Chromosomes Cancer2000; 27: 95–103.
38.
BrennanC.M., SteitzJ.A.. HuR and mRNA stability.Cell Mol Life Sci2001; 58: 266–77.
39.
JacobsE.J., RodriguezC., MondulA.M.A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence.J Natl Cancer Inst2005; 97: 975–80.
40.
BarbisanFrancesca, MazzucchelliRoberta, SantinelliAlfredoOverexpression of ELAV-like protein HuR is associated with increased COX-2 expression in proliferative inflammatory atrophy, high-grade prostatic intraepithelial neoplasia and incidental prostate cancer in cystoprostatectomies.Eur Urol (Submitted) 2008.
41.
ShayJ.W., WerbinH., WrightW.E.. Telomerere shortening may contribute to aging and cancer: a perspective.Mol Cell Differ1994; 2: 1–22.
42.
IczkowskiK.A., PantazisC.G., McGregorD.H., WuY., TawfikO.W.. Telomerase reverse transcriptase subunit immunoreactivity: a marker for high-grade prostate carcinoma.Cancer2002; 95: 2487–93.
43.
LiuB.C., LaRoseI., WeinsteinL.J., AhnM., WeinsteinM.H., RichieJ.P.. Expression of telomerase subunits in normal and neoplastic prostate epithelial cells isolated by laser capture microdissection.Cancer2001; 92: 1943–48.
44.
WangZ., RaminS.A., TsaiC.Detection of telomerase activity in prostatic fluid specimens.Urol Oncol2000; 6: 4–9.
45.
WangZ., RaminS.A., TsaiC.Telomerase activity in prostate sextant needle cores from radical prostatectomy specimens.Urol Oncol2001; 6: 57–62.
46.
ZhangW., KapustaL.R., SlingerlandJ.M., KlotzL.H.. Telomerase activity in prostate cancer, prostatic intraepithelial neoplasia, and benign prostatic epithelium.Cancer Res1998; 58: 619–21.
47.
DonaldsonL., FordyceC., GillilandF.Association between outcome and telomere DNA content in prostate cancer.J Urol1999; 162: 1788–92.
48.
PatelY.C.. Somatostatin and its receptor family.Front Neuroendocrinol1999; 20: 157–98.
49.
VersetG., VerslypeC., ReynaertH.Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study.Br J Cancer2007; 97: 582–88.
50.
DizeyiN., KonradL., BjartellA.Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell lines.Urol Oncol2002; 7: 1–98.
51.
MontironiR., ChengL., MazzucchelliR.Immunohistochemical detection and localization of somatostatin receptor subtypes in prostate tissue from patients with bladder outlet obstruction.Cell Oncology (Accepted) 2008.
52.
SimonJP, AunisD.. Biochemistry of the chromogranin A protein family.Biochem J1989; 262: 1–13.
53.
BlaschkoH., ComlineR.S., SchneiderF.H., SilverM., SmithA.D.. Secretion of a chromaffin granule protein, chromogranin, from the adrenal gland after splanchnic stimulation.Nature1967; 215: 58–9.
54.
BerrutiA., DogliottiL., MoscaA.Potential clinical value of circulating chromogranin A in patients with prostate carcinoma.Ann Oncol2001; 12: S153–7.
55.
WuJ.T., EricksonA.J., TsaoK.C., WuT.L., SunC.F.. Elevated serum chromogranin A is detectable in patients with carcinomas at advanced disease stages.Ann Clin Lab Sci2000; 30: 175–8.
56.
ChevilleJ.C., TindallD., BoelterC.Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival.Cancer2002; 95: 1028–36.
57.
AhlegrenG., PedersenK., LundbergS., AusG., HugossonJ., AbrahamssonP.. Neuroendocrine differentiation is not prognostic of failure after radical prostatectomy but correlates with tumor volume.Urology2000; 56: 1011–15.
58.
LillebyW., PausE., SkovlundE., FossåS.D.. Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer.Prostate2001; 46: 126–33.
59.
Zaky AhelM., KovacicK., KraljicI., TarleM.. Oral estramustine therapy in serum chromogranin A-positive stage D3 prostate cancer patients.Anticancer Res2001; 21: 1475–79.
60.
IsshikiS., AkakuraK., KomiyaA., SuzukiH., KamiyaN., ItoH.. Chromogranin A concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer.J Urol2002; 167: 512–15.
